Among patients with advanced cancer who were prescribed immune checkpoint inhibitors, those who experienced skin-related side effects were significantly less likely to die. The findings may help clinicians counsel patients who develop skin-related side effects of immunotherapy and determine the effectiveness of these medications in individual patients.